Back to Search
Start Over
CONSISTENCY OF LDL-C REDUCTION WITH EVOLOCUMAB: AN ANALYSIS FROM FOURIER
- Source :
- Journal of the American College of Cardiology. 71:A1727
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- Questions have been raised about interpatient variability in response to PCSK9 inhibitors. FOURIER was a randomized, pbo-controlled trial of the PCSK9i evolocumab, a fully human mAb, in pts w/ ASCVD on a statin. We examined % change in LDL-C at 4 wks. Pts in either arm who did not receive study
- Subjects :
- Oncology
medicine.medical_specialty
Statin
business.industry
medicine.drug_class
macromolecular substances
Reduction (complexity)
Evolocumab
symbols.namesake
Fourier transform
Consistency (statistics)
Internal medicine
otorhinolaryngologic diseases
symbols
Medicine
Cardiology and Cardiovascular Medicine
business
PCSK9 Inhibitors
Subjects
Details
- ISSN :
- 07351097
- Volume :
- 71
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.doi...........cdb4a332007c0a5850b3889309181fbd